Literature DB >> 23589532

A second chance to tackle African malaria vector mosquitoes that avoid houses and don't take drugs.

Gerry F Killeen.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23589532      PMCID: PMC3752742          DOI: 10.4269/ajtmh.13-0065

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


× No keyword cloud information.
Sometimes history gives us a second chance by repeating itself. The timely and lucid modeling analysis presented by Phillip Eckhoff in this issue1 reminds us all that the challenges and opportunities faced by the malaria control community today remain remarkably similar to those of our predecessors who undertook the Global Malaria Eradication Campaign (GMEP). The anti-malarial drugs we use in 2013 are relatively new to the front lines but they are still overwhelmingly used in the same way for reactive clinical management of symptomatic cases.2 Long-lasting insecticidal nets (LLINs) now offer a proven alternative to indoor residual spraying (IRS) as the front-line vector control tool of the GMEP era but both approaches target mosquitoes within the same indoor environment and evidence that combining the two yields incremental benefits remains mixed.3–7 Although efficacious vaccines against malaria now exist and their expected impacts are simulated here,1 the protection they confer is partial and may wane8 as naturally acquired immunity fades9 and/or naturally acquired skin stage infections induce immunotolerance of pre-erythrocytic stages.10 Therefore, the fundamental properties, applications, and limitations of “off-the-shelf” intervention options available to control program managers today have not dramatically changed since the heyday of GMEP optimism half a century ago.11 And neither have the most fundamental knowledge gaps we face. The white arrows in Figure 1 crudely illustrate the impacts of intervention strategies we have reasonable experience and understanding of (suppression of high transmission with LLINs or IRS and elimination of sparse residual human parasite reservoirs with drugs), whereas the dark arrows illustrate those we urgently need to develop and learn about through trial and error (long-term resistance management, programmatic-scale vector control outdoors or at source, elimination of mosquito-to-human transmission during the dry season with vaccines, novel vector control tools, or chemoprophylaxis).
Figure 1.

A schematic representation of the sequential layers of intervention required to eliminate malaria from the most staunchly endemic regions of Africa in the long term and where we stand in terms of best practice today or 50 years ago during the Global Malaria Eradication Program.

A schematic representation of the sequential layers of intervention required to eliminate malaria from the most staunchly endemic regions of Africa in the long term and where we stand in terms of best practice today or 50 years ago during the Global Malaria Eradication Program. The four major issues highlighted by this intricate set of simulations, using a remarkably flexible and extendable modeling architecture, are as follows. 1) We need more intervention layers of vector and parasite control to eliminate malaria from African settings than we presently have available. 2) Options for vector control outdoors or at source remain conspicuous by their absence. 3) Although recently developed vaccines narrow this gap, between the control levels we can achieve today and the elimination target we have set for ourselves, they do not fill it. 4) Parasite populations are buffered against extinction by low levels of persisting transmission during the dry season, which represents a far more manageable target for targeted intervention than peaks of transmission associated with the rainy season. Although none of these insights are entirely unprecedented, they have never before been given such explicit emphasis and integrated consideration as the obstacles we must overcome to eliminate malaria from equatorial Africa. Furthermore, the timing could not possibly be better: These predictions that dramatic reductions of transmission can be achieved in Africa parallels reality on the ground in many countries today, while at the same time, the global financial support base for national control programs is in clear and present danger. Less than 6 years have passed since the dramatic reprioritization of local, national and regional elimination, ultimately leading to worldwide eradication, as the long-term goal of the global malaria control strategy.12 Since then, high coverage with proven vector control methods and effective drugs has become increasingly commonplace and saves hundreds of thousands of lives annually.13–15 However, elimination of transmission from African settings remains as elusive as ever, even in settings where these historical cornerstones of malaria control have been supplemented by the most advanced malaria vaccine available.8 As explained using an unusually explicit and detailed model,1 the most effective intervention technologies available today have largely delivered on reasonable expectations but their fundamental limitations persist because the biology of malaria parasites and vectors have not changed. Unlike the GMEP generation, we have the privilege of hindsight, embraced malaria elimination and eradication goals fully informed by historical precedents, and should be encouraged that we now find ourselves at this difficult but predictable crossroads again so soon. The recent rapid gains in both coverage and impact of LLINs and IRS are massive and unprecedented but also worryingly fragile.13 The immediate threat of funding stagnation, or even contraction, belies an even more dangerous loss of confidence by the global public based on media emphasis of the know limitations of established control technologies that still “do what they say on the tin” but no more. So what was written in the historical fine print on the side of the tin that this article illuminates for us? What are the scientific, implementation, and stakeholder engagement issues this article raises? More to the point, how should we address them now that history has given us a second chance? First, this article outlines in great detail why layering of all available effective interventions (vector control in the form of LLINs or IRS, therapeutic drugs, and vaccines) is required to reduce transmission levels to manageable levels but is unlikely to extinguish it from many parts of sub-Saharan Africa where it can exceed minimum stability thresholds by up to four orders of magnitude (Figure 1). Although the exceptional positive externality delivered by the community level impact, or the mass effect, of LLINs or IRS can indeed reduce transmission by two orders of magnitude, a very small fraction of a very, very, very big number is still a very big number. Most countries in sub-Saharan Africa have historically experienced the full range of baseline transmission intensities described in Figure 1 and it is the exceptional, most extreme values in the top right corner that bolster parasite populations against our best efforts to eliminate them.16,17 Settings exist somewhere in most nations of equatorial Africa where optimal conditions for propagation of malaria parasites (R0 approaching 10,000, entomologic inoculation (EIR) approaching 1,000) necessitate 99.99% control to push reproductive numbers below the threshold at which local extinction occurs (R0 < 1). To do so will require that we not only sustain 99% suppression of indoor transmission with the vector control tools we already have: we must also develop and apply complementary tools that layer on a further 99% impact by controlling vectors outdoors and at source. The wide range across which African malaria transmission intensity has historically varied (Figure 1) therefore creates the counterintuitive situation in which successful application of the best tools available can be accurately and simultaneously described, as a glass that is either almost full or almost empty. Thus, a given level of impact on malaria transmission can be accurately described as either highly successful control or abject failure to eliminate it: The combination of mass administration of sulfalene-pyrimethamine with residual spraying of propoxur failed to interrupt transmission for any length of time. This was true even when drugs were given every 2 weeks in the wet season and every 10 weeks in the dry season with coverage of 85%. A high level of control was, however, achieved at that frequency of mass drug administration (MDA): the prevalence of parasitemia decreased very rapidly and varied in the l–5% range, according to season.18 The correct interpretation of contemporary progress along the logarithmic scales in Figure 1 is that we are approximately half way along the road to elimination from areas of such intense transmission. As elegantly outlined by Eckhoff, the glass is half full and this situation is neither surprising nor unprecedented. The primary immediate threat to sustained malaria control is neither the results of such simulations, nor parallel empirical observations from the field, but rather the way in which we formulate and communicate our interpretation of them. We should all therefore carefully consider past errors of interpretation that ultimately caused collapse of public and political support for the GMEP, and for malaria control generally, for decades afterward. Would any of us agree with the following statements today? It may be concluded that in the rural areas of the Sudan savanna of Africa residual spraying is not to be recommended as a malaria control method.18 It may not be feasible at an acceptable cost at the present time to control malaria in the rural areas of the Sudan savanna by an attack on transmission. It should, however, be possible to reduce the morbidity and mortality as a result of malaria by the treatment of clinical cases.18 Despite valid concerns regarding physiological resistance to insecticides,19 and clear evidence of vector population rebound in two cases,20–22 IRS and LLINs continue to deliver the valuable levels of transmission control predicted by Eckhoff in most contexts.13–15 Encouragingly, pyrethroid resistance was successfully managed in the South African example by reverting to DDT as the active ingredient for IRS, so that vector control and even elimination has been sustained on a national scale for half a century with only one major interruption.22,23 Recent evidence of rebounding vector populations and malaria transmission in Senegal soon after LLIN introduction,20 is undoubtedly worrying. Furthermore, resistance management strategies for nets are far more challenging because direct contact with the user currently limits choice of active ingredients to a single insecticides class—the pyrethroids upon which we have become so dangerously dependent. Nevertheless, in most parts of Africa the glass remains half full for now.13–15 Weakening global commitment to support delivery of these proven life-saving measures, arising from the perception of a half-empty glass, represents an equally important and immediate threat to successful malaria control programs in Africa today. Sharing a balanced view of our long-term struggle with the global public, and sustaining political will to save lives with the tools we have now, is as important, challenging, and achievable as managing insecticide resistance among mosquitoes. Central to that communication strategy must be open acceptance that we will need to enhance and maintain delivery of current interventions for many decades, generations, or even indefinitely. The real beauty of an eradication strategy is that even if you never ultimately achieve it, vast numbers of lives and dollars are saved in the attempt so long as indefinite timelines for sustaining control and elimination programs are formally incorporated into policy, practice, and funding mechanisms. It is therefore vital that we simply keep trying, never give up, and convince the global public to formalize this philosophy in global funding mechanisms. If we really wish to go further than the boom-and-bust experience of the GMEP, we have to accept the uncomfortable truth that setbacks must be expected and stubbornly tackled as part of our long-term strategy. We cannot allow the political history of GMEP to repeat itself. The second major facet of malaria transmission and control elucidated by Eckhoff is the robust buffering of malaria transmission against IRS and LLIN impact by vectors that feed or rest outdoors. In other words, the most obvious missing layer from the intervention suite described in Figure 1 is vector control of adult mosquitoes outside of houses or immature aquatic stages at source. Even for the most potently anthropophagic but conveniently endophagic African vectors, a minority transmission has always naturally occurred outdoors (Figure 2). This small gap in protective coverage28 typically represents at least half of the residual transmission experienced by LLIN users in Africa, even without assuming any induced change in vector population composition or behavior: As depicted in Figure 2, an average of 55% of LLIN user exposure to members of the Anopheles gambiae complex is estimated to occur outdoors and 66% for Anopheles funestus.
Figure 2.

Estimates of the proportion of human exposure to African vector populations for users (πi,n) and non-users (πi) of long-lasting insecticidal nets (LLINs). All estimates of πi for vector populations in Kenya, Tanzania, Zambia, and Burkina Faso were obtained directly from a recently published analysis.24 For Anopheles gambiae in Equatorial Guinea, an approximate value was derived from published estimates25 of the proportion of mosquitoes caught indoors (Pi) and the proportion caught during the first and last hours that the majority of residents were considered to be asleep indoors (Pfl): πi = Pfl Pi/[Pfl Pi + (1 − Pfl)(1 − Pi]. Values for πi,n were calculated without explicit calculation of hourly behavior-weighted biting rates, discounted for indoor personal protection (ρ), as originally described for Anopheles funestus and Anopheles quadriannulatus in Zambia.26 Instead πi,n was calculated based on these estimates of πi and a mean of published estimates27 for the personal protection provided by an LLIN (ρ = 0.937): πi,n = πi (1 − ρ)/[πi (1 − ρ) + (1 − πi)]. Note that Figure 3 and the abstract of the original report from Zambia26 mistakenly report a cruder binomial estimate for the proportion of non-user exposure occurring indoors (described by Equation 4 of Seyoum and others and distinguished as πiB in Huho and others) rather than the more refined estimate based on mosquito biting rates weighted according population mean human behavior (described as Equation 1 in Seyoum and others and annotated as πi in both works), which are described in Figure 3 of Huho and others and used to derive the πi,n estimates presented here.

Estimates of the proportion of human exposure to African vector populations for users (πi,n) and non-users (πi) of long-lasting insecticidal nets (LLINs). All estimates of πi for vector populations in Kenya, Tanzania, Zambia, and Burkina Faso were obtained directly from a recently published analysis.24 For Anopheles gambiae in Equatorial Guinea, an approximate value was derived from published estimates25 of the proportion of mosquitoes caught indoors (Pi) and the proportion caught during the first and last hours that the majority of residents were considered to be asleep indoors (Pfl): πi = Pfl Pi/[Pfl Pi + (1 − Pfl)(1 − Pi]. Values for πi,n were calculated without explicit calculation of hourly behavior-weighted biting rates, discounted for indoor personal protection (ρ), as originally described for Anopheles funestus and Anopheles quadriannulatus in Zambia.26 Instead πi,n was calculated based on these estimates of πi and a mean of published estimates27 for the personal protection provided by an LLIN (ρ = 0.937): πi,n = πi (1 − ρ)/[πi (1 − ρ) + (1 − πi)]. Note that Figure 3 and the abstract of the original report from Zambia26 mistakenly report a cruder binomial estimate for the proportion of non-user exposure occurring indoors (described by Equation 4 of Seyoum and others and distinguished as πiB in Huho and others) rather than the more refined estimate based on mosquito biting rates weighted according population mean human behavior (described as Equation 1 in Seyoum and others and annotated as πi in both works), which are described in Figure 3 of Huho and others and used to derive the πi,n estimates presented here.
Figure 3.

A schematic representation of how parasite populations can “leap-frog” mass drug administration (or mass screen and treat) interventions by surviving as purely sporogonic stages unless vector-to-human transmission is terminated for at least 2 months.

However, it is often the less anthropophagic, and correspondingly less potent, primary vectors that usually present the greatest obstacle to malaria elimination. Weaker, but nevertheless important, vectors like Anopheles arabiensis transmit less malaria but are correspondingly less vulnerable to LLINs and IRS because they are far less dependent upon human blood.28,29 Taking An. arabiensis as an excellent African example, such zoophagic primary vectors often also exhibit significant exophagy and exophily so that they are resilient to attack within houses using LLINS or IRS. As beautifully outlined with the best empirical data30–32 and models33 available at the end of the GMEP, the simulations presented here by Eckhoff confirm that heterogeneity of vector population behaviors present a diverse set of targets that no single vector control measure can effectively tackle.1 Recent studies of residual transmission systems where highly endophagic mosquitoes have been effectively tackled by IRS or LLINs remind us that behavioral avoidance of indoor insecticide exposure, by such a naturally evasive species as An. arabiensis,6,7,34,35 does not necessarily represent failure, or even waning impact, of these measures but rather their inherent limitations from the outset.18,31–33,36–38 Recent reports of surprising39 and previously undescribed40 primary vectors most probably does not reflect the emergence of new vector systems but rather that their role in transmission is now more obvious because they are no longer outnumbered by An. gambiae and An. funestus. Crucially, none of the simulations of Eckhoff assume any selection-induced change in such behaviors1 and are therefore consistent with the long-established view18,31–33,36 that pre-existing behavioral preferences or plasticity define the limits of what is possible with IRS or LLINs before a single house is sprayed or a single net distributed. Although the term behavioral resistance has been applied to the zoophagic, exophagic and exophilic habits of such robust vector populations, this may be misleading because physiological resistance to insecticides is defined in terms of altered frequencies of heritable traits: Insecticide resistance (WHO): The ability of an insect to withstand the effects of an insecticide by becoming resistant to its toxic effects by means of natural selection and mutations. Operational field resistance (Insecticide Resistance Action Committee): A heritable change in the sensitivity of a pest population that is reflected in the repeated failure of a product to achieve the expected level of control when used according to the label recommendation for that pest species.19 The term behavioral resilience, as applied to the stability of ecological systems,41 may therefore be more appropriate to describe the pre-existing evasive traits that stabilize the tripartite relationship between vectors, parasites, and humans against perturbation with indoor vector control measures, in such robust transmission ecosystems. The analysis of vaccine impact upon transmission stability clearly illustrates how the success of each additional intervention layer depends on the success and limitations of those which it supplements. For example, whereas curative drugs can suppress human-to-mosquito transmission in some settings where mosquito-to-human transmission intensity is quite low,42–45 negligible impact upon transmission has been observed in rural African settings46–49 where rapid re-infection rates stabilize saturated human reservoirs of parasites.2,50 Here, this principle is extended to vaccines with similar conclusions that parallel those of similar analyses by others9: at current levels of efficacy, vaccines will enhance malaria control impact and narrow the gap between the two white arrows in Figure 1 but will not close it. As elegantly outlined by Eckhoff, the modest attenuation of LLIN and IRS impact by zoophagic, exophagic, and exophilic primary vectors simply leaves far too high a level of residual transmission for conventional drug or vaccine-based strategies to completely mop up the reservoir of parasite infection.1 Perhaps the most important issue highlighted by these simulations is the critical importance of dry season transmission in stabilizing populations of falciparum malaria. Most transmission of Plasmodium falciparum malaria occurs in predictable annual peaks during, or soon after, rainy periods. These peaks account for the vast majority of cumulative malaria transmission and correspondingly attract most attention from malariologists. However, the minority fraction of transmission that occurs during annual minima, typically during the dry season, may actually be a more important determinant of success or failure. As originally highlighted in Figure 77 of the historic Garki monograph,18 suppression and elimination of P. falciparum populations within humans is, by definition, always going to be easiest to achieve during annual dry seasons and periodic droughts when rates of human re-infection are lowest, particularly in localities where vector-borne transmission actually reaches zero rather than merely approaching it. The persistence of low but non-zero transmission in foci of perennial vector breeding bolsters P. falciparum populations against the effects of vector control and vaccine products that may remain efficacious for months or even years. However, the implications for how best we use anti-malarial drugs with half lives of hours, days, or weeks merit special consideration. Unlike Plasmodium vivax, which can survive for years hidden cryptically as hypnozoites within the liver of its human hosts,51 P. falciparum must primarily survive seasonal and periodic minima of transmission as blood stages that are vulnerable to treatment with curative drugs. However, asexual blood stages, and the infectious sexual-stage gametocytes they give rise to, enable temporary escape from the human body as sporogonic stages living in the bodies of mosquitoes that may survive for up to 14 feeding cycles, equivalent to at approximately one and a half months.52 The fact that sporogonic stage infections can persist longer than single complete doses of therapeutic drugs enables P. falciparum populations to partially evade such exclusively human-directed chemical attack for the simple reason that mosquitoes do not take drugs. Although the benefits of controlling reservoirs of human parasite infection with therapeutic drugs are intuitive, appealing, and well established, only limited impact can be expected where high transmission levels persist18,46,50,53 and the dangers of applying strong selection pressure for drug resistance upon robust parasite populations are also obvious.50 These observations have a number of very important and direct implications for the final stages of P. falciparum elimination. First of all, the ability of parasite populations to “leap frog” well implemented drug distribution campaigns (Figure 3) inherently depends on opportunities to infect mosquitoes; therefore, the best time to implement these is when the size of the sporogonic-stage parasite population and rate of human re-infection from this flying reservoir is minimized.2 The final stage of malaria elimination programs in many areas of currently stable endemic transmission will most probably rely upon drug therapy campaigns to remove persisting human infections.2,54,55 Some notable successes have been reported from areas of modest endemicity42–45 where theory suggests that anti-parasitic drugs may have their greatest impact.50,53,54 Consistent with the post-GMEP view, all theoretical, observational and experimental studies since then confirm that population-wide drug administration campaigns have limited impact upon the high levels of transmission commonly observed in sub-Saharan Africa, even when layered upon an effective vector control intervention48–50: A schematic representation of how parasite populations can “leap-frog” mass drug administration (or mass screen and treat) interventions by surviving as purely sporogonic stages unless vector-to-human transmission is terminated for at least 2 months. Previous trials using the combination of MDA and residual spraying in the Sudan savanna of Africa had achieved variable degrees of control, but all had failed to interrupt transmission.18 MDA strategies entail treating entire populations without any diagnostic surveys to determine their infection status,48 whereas mass screening and treatment (MSAT), historically referred to as mass blood examination,56 entails a diagnostic census with treatment provided to all population members confirmed to be infected with parasites. Both of these approaches rely upon achieving comprehensive coverage of at risk populations, as well as high levels of drug efficacy, compliance, and adherence. The Achilles' heel of both these strategies is the inherent assumption that the entire parasite population is accessible to drug treatment within the bodies of human secondary hosts. The mosquitoes that act as primary hosts for Plasmodia are obviously non-adherent to any drug regimen so the sporogonic stages that occur in the airborne vector population remain beyond the reach of MDA and MSAT. Figure 4 illustrates just how many sporogonic-stage infections may be present in even quite modestly-sized human communities with very low seasonal transmission minima. To get these figures into perspective, a daily EIR inoculation rate of 0.001 infectious bites per person per day is equivalent to an annual rate of only 0.365 infectious bites per person per year and could readily escape detection with standard entomological survey methods.57 It is also equivalent to a monthly rate of ∼0.03 infectious bites per person per month, a level matched or comfortably exceeded by the reported EIR minima for 5 of the 6 African settings examined in another excellent recent theoretical analysis of prospects for malaria elimination using existing vector control and chemotherapy tools.38 The levels of malaria transmission that often persist throughout the dry season in African communities can therefore keep dozens, hundreds or even thousands of individual parasite infections safe from the effects of anti-parasitic drugs inside the bodies of mosquitoes. To prevent reinitiation of endemic transmission by mosquito-borne parasite stages, it will be essential to completely suppress mosquito-to-human transmission for at least 2 months after a mass drug administration program. It has therefore been suggested that dry season MDA interventions should be supplemented with a correspondingly timed supplementary round of IRS to minimize human re-infection rates38 and that radical cure should be followed by a period of prophylaxis at least as long as the maximum life span of the mosquito.2
Figure 4.

Relationship between the total number of sporozoite-stage infections of mosquitoes (Ns) present in human communities of varying size (Nh) with varying minimum levels of human-to-mosquito transmission, expressed as the daily entomologic inoculation rate (EIRmin). A mean feeding cycle length of 3 days (f = 3) was assumed so that the size of the sporozoite-stage parasite population could be calculated as Ns = EIRmin f Nh.

Relationship between the total number of sporozoite-stage infections of mosquitoes (Ns) present in human communities of varying size (Nh) with varying minimum levels of human-to-mosquito transmission, expressed as the daily entomologic inoculation rate (EIRmin). A mean feeding cycle length of 3 days (f = 3) was assumed so that the size of the sporozoite-stage parasite population could be calculated as Ns = EIRmin f Nh. Integrating this logic into the picture outlined by the simulations presented in this issue1 prompts a number of further strategic recommendations. 1) It is essential to judiciously plan the sequence in which malaria control intervention are layered to optimize levels of impact and maximize chances of sustained control or successful elimination. 2) Novel vaccine, vector control, and chemoprophylaxis strategies that prevent mosquito-to-human transmission for at least 2 months during the dry season should precede any MDA or MSAT campaign in the layering sequence. 3) These complementary measures need not necessarily be implemented or deliver valuable impact throughout the year so long as they do so during the dry season, specifically in the limited geographic foci where transmission persists all year round. 4) Vector control measures that exploit the specific ecology of mosquitoes during the dry season and the practical logistic advantages of this period could readily fill the intervention gap in the middle of Figure 1. 5) Primary vectors such as An. funestus that are known to predominantly depend on perennial aquatic habitats, and therefore mediate a disproportionate amount of dry season transmission, merit correspondingly weighted attention. 6) MDA or MSAT should only be considered as end-game strategies in malaria elimination for situations where confidence of success, established by impacts of preceding intervention layers, is high and should use alternative therapeutic drugs to those essential for treating clinical cases to minimize risk of compromising their efficacy by selecting for resistance. The GMEP was defeated by dry season transmission, and by mosquitoes which avoid houses, because it simply ignored them, never took them on, and did not acknowledge their importance until it was too late. These are challenges that can be feasibly addressed, however. Ample opportunity now exists to finally tackle these robust minor fractions of transmission58–60 that have always existed but only become obvious as obstacles to elimination once the bulk of transmission occurring indoors during the rainy season has been suppressed. This, however, will take time and investment. In the meantime, we need to defend the efficacy, financial support base, and delivery capacity for the interventions we already have and remain dependent on for at least another decade. History has given us a second chance on both counts. And history will judge us.
  56 in total

Review 1.  Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control?

Authors:  Hilary Ranson; Raphael N'guessan; Jonathan Lines; Nicolas Moiroux; Zinga Nkuni; Vincent Corbel
Journal:  Trends Parasitol       Date:  2010-09-16

2.  Malaria. Did they really say ... eradication?

Authors:  Leslie Roberts; Martin Enserink
Journal:  Science       Date:  2007-12-07       Impact factor: 47.728

Review 3.  Chromosomal differentiation and adaptation to human environments in the Anopheles gambiae complex.

Authors:  M Coluzzi; A Sabatini; V Petrarca; M A Di Deco
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

4.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

Review 5.  Operational strategies to achieve and maintain malaria elimination.

Authors:  Bruno Moonen; Justin M Cohen; Robert W Snow; Laurence Slutsker; Chris Drakeley; David L Smith; Rabindra R Abeyasinghe; Mario Henry Rodriguez; Rajendra Maharaj; Marcel Tanner; Geoffrey Targett
Journal:  Lancet       Date:  2010-10-28       Impact factor: 79.321

6.  A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.

Authors:  Seif A Shekalaghe; Chris Drakeley; Sven van den Bosch; Roel ter Braak; Wouter van den Bijllaardt; Charles Mwanziva; Salimu Semvua; Alutu Masokoto; Frank Mosha; Karina Teelen; Rob Hermsen; Lucy Okell; Roly Gosling; Robert Sauerwein; Teun Bousema
Journal:  Malar J       Date:  2011-08-24       Impact factor: 2.979

7.  Simplified models of vector control impact upon malaria transmission by zoophagic mosquitoes.

Authors:  Samson S Kiware; Nakul Chitnis; Sarah J Moore; Gregor J Devine; Silas Majambere; Stephen Merrill; Gerry F Killeen
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 8.  Experimental, therapeutic and natural transmission of Plasmodium vivax tertian malaria: scientific and anecdotal data on the history of Dutch malaria studies.

Authors:  Jan Peter Verhave
Journal:  Parasit Vectors       Date:  2013-01-18       Impact factor: 3.876

Review 9.  The role of anti-malarial drugs in eliminating malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

10.  Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings.

Authors:  Philip Eckhoff
Journal:  Am J Trop Med Hyg       Date:  2013-04-15       Impact factor: 2.345

View more
  34 in total

1.  Modulating malaria with Wolbachia.

Authors: 
Journal:  Nat Med       Date:  2013-08       Impact factor: 53.440

2.  The Impact of 3 Years of Targeted Indoor Residual Spraying With Pirimiphos-Methyl on Malaria Parasite Prevalence in a High-Transmission Area of Northern Zambia.

Authors:  Marisa A Hast; Mike Chaponda; Mbanga Muleba; Jean-Bertin Kabuya; James Lupiya; Tamaki Kobayashi; Timothy Shields; Justin Lessler; Modest Mulenga; Jennifer C Stevenson; Douglas E Norris; William J Moss
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

3.  Variation in the effectiveness of insecticide treated nets against malaria and outdoor biting by vectors in Kilifi, Kenya.

Authors:  Alice Kamau; Joseph M Mwangangi; Martin K Rono; Polycarp Mogeni; Irene Omedo; Janet Midega; J Anthony G Scott; Philip Bejon
Journal:  Wellcome Open Res       Date:  2018-12-03

4.  Mapping hotspots of malaria transmission from pre-existing hydrology, geology and geomorphology data in the pre-elimination context of Zanzibar, United Republic of Tanzania.

Authors:  Andrew Hardy; Zawadi Mageni; Stefan Dongus; Gerry Killeen; Mark G Macklin; Silas Majambare; Abdullah Ali; Mwinyi Msellem; Abdul-Wahiyd Al-Mafazy; Mark Smith; Chris Thomas
Journal:  Parasit Vectors       Date:  2015-01-22       Impact factor: 3.876

5.  Predicting Scenarios for Successful Autodissemination of Pyriproxyfen by Malaria Vectors from Their Resting Sites to Aquatic Habitats; Description and Simulation Analysis of a Field-Parameterizable Model.

Authors:  Samson S Kiware; George Corliss; Stephen Merrill; Dickson W Lwetoijera; Gregor Devine; Silas Majambere; Gerry F Killeen
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

6.  Applications and limitations of Centers for Disease Control and Prevention miniature light traps for measuring biting densities of African malaria vector populations: a pooled-analysis of 13 comparisons with human landing catches.

Authors:  Olivier J T Briët; Bernadette J Huho; John E Gimnig; Nabie Bayoh; Aklilu Seyoum; Chadwick H Sikaala; Nicodem Govella; Diadier A Diallo; Salim Abdullah; Thomas A Smith; Gerry F Killeen
Journal:  Malar J       Date:  2015-06-18       Impact factor: 2.979

7.  Habitat hydrology and geomorphology control the distribution of malaria vector larvae in rural Africa.

Authors:  Andrew J Hardy; Javier G P Gamarra; Dónall E Cross; Mark G Macklin; Mark W Smith; Japhet Kihonda; Gerry F Killeen; George N Ling'ala; Chris J Thomas
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

Review 8.  Eliminating malaria vectors.

Authors:  Gerry F Killeen; Aklilu Seyoum; Chadwick Sikaala; Amri S Zomboko; John E Gimnig; Nicodem J Govella; Michael T White
Journal:  Parasit Vectors       Date:  2013-06-07       Impact factor: 3.876

9.  Entomological surveillance of behavioural resilience and resistance in residual malaria vector populations.

Authors:  Nicodem J Govella; Prosper P Chaki; Gerry F Killeen
Journal:  Malar J       Date:  2013-04-11       Impact factor: 2.979

10.  Potential causes and consequences of behavioural resilience and resistance in malaria vector populations: a mathematical modelling analysis.

Authors:  Gerry F Killeen; Nakul Chitnis
Journal:  Malar J       Date:  2014-03-14       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.